Detalhe da pesquisa
1.
HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide.
Blood
; 139(10): 1452-1468, 2022 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34724567
2.
FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Follicular Lymphoma.
Oncologist
; 27(7): 587-594, 2022 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35403693
3.
FDA approval summary: Crizotinib for pediatric and young adult patients with relapsed or refractory systemic anaplastic large cell lymphoma.
Pediatr Blood Cancer
; 69(8): e29602, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35561013
4.
FDA Approval Summary: Selinexor for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Oncologist
; 26(10): 879-886, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34132444
5.
Guidelines for Reporting Trial Protocols and Completed Trials Modified Due to the COVID-19 Pandemic and Other Extenuating Circumstances: The CONSERVE 2021 Statement.
JAMA
; 326(3): 257-265, 2021 07 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34152382
6.
FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell Lymphoma.
Oncologist
; 24(5): e180-e187, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30914464
7.
Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide.
Blood
; 129(10): 1389-1393, 2017 03 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28049637
8.
Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide.
Biol Blood Marrow Transplant
; 24(2): 343-352, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29055682
9.
Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation.
Biol Blood Marrow Transplant
; 24(5): 1022-1028, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29353109
10.
Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related Donors.
Biol Blood Marrow Transplant
; 24(5): 1099-1102, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29452245
11.
FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis.
Oncologist
; 23(12): 1511-1519, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30115735
12.
The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint.
Lancet Oncol
; 23(5): 563-566, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35429996
13.
Post-Transplantation Cyclophosphamide after Bone Marrow Transplantation Is Not Associated with an Increased Risk of Donor-Derived Malignancy.
Biol Blood Marrow Transplant
; 23(4): 612-617, 2017 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-28062216
14.
Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies.
Biol Blood Marrow Transplant
; 23(2): 325-332, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27888014
15.
FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma.
Oncologist
; 22(5): 585-591, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28438889
16.
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide.
Blood
; 125(19): 3024-31, 2015 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-25814532
17.
Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.
Haematologica
; 102(2): 391-400, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27846611
18.
Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS.
Blood
; 124(25): 3817-27, 2014 Dec 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-25316679
19.
ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma.
Haematologica
; 101(8): 968-75, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27151994
20.
Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors.
Biol Blood Marrow Transplant
; 21(12): 2115-2122, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26183076